Trial · NCT02251275
Adverse events1,605
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,605
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Left Ventricular Hypertrophy | Cardiac disorders | Tolvaptan (From 156-13-210: Tolvaptan) | 0 | 505 | 0 |
| other | Left Ventricular Hypertrophy | Cardiac disorders | Tolvaptan (From 156-13-210: Placebo) | 0 | 569 | 0 |
| other | Left Ventricular Hypertrophy | Cardiac disorders | Tolvaptan (From 156-08-271: Tolvaptan) | 0 | 717 | 0 |
| other | Left Ventricular Hypertrophy | Cardiac disorders | Tolvaptan (From Other: Tolvaptan) | 1 | 6 | 1 |
| other | Left Ventricular Hypertrophy | Cardiac disorders | Tolvaptan (From Other: Placebo) | 0 | 3 | 0 |
| other | Palpitations | Cardiac disorders | Tolvaptan (From 156-13-210: Tolvaptan) | 5 | 505 | 5 |
| other | Palpitations | Cardiac disorders | Tolvaptan (From 156-13-210: Placebo) | 6 | 569 | 6 |
| other | Palpitations | Cardiac disorders | Tolvaptan (From 156-08-271: Tolvaptan) | 14 | 717 | 15 |
| other | Palpitations | Cardiac disorders | Tolvaptan (From Other: Tolvaptan) | 1 | 6 | 1 |
| other | Palpitations | Cardiac disorders | Tolvaptan (From Other: Placebo) | 0 | 3 | 0 |
| other | Hypoacusis | Ear and labyrinth disorders | Tolvaptan (From 156-13-210: Tolvaptan) | 3 | 505 | 3 |
| other | Hypoacusis | Ear and labyrinth disorders | Tolvaptan (From 156-13-210: Placebo) | 0 | 569 | 0 |
| other | Hypoacusis | Ear and labyrinth disorders | Tolvaptan (From 156-08-271: Tolvaptan) | 1 | 717 | 1 |
| other | Hypoacusis | Ear and labyrinth disorders | Tolvaptan (From Other: Tolvaptan) | 1 | 6 | 1 |
| other | Hypoacusis | Ear and labyrinth disorders | Tolvaptan (From Other: Placebo) | 0 | 3 | 0 |
| other | Motion Sickness | Ear and labyrinth disorders | Tolvaptan (From 156-13-210: Tolvaptan) | 1 | 505 | 1 |
| other | Motion Sickness | Ear and labyrinth disorders | Tolvaptan (From 156-13-210: Placebo) | 1 | 569 | 1 |
| other | Motion Sickness | Ear and labyrinth disorders | Tolvaptan (From 156-08-271: Tolvaptan) | 0 | 717 | 0 |
| other | Motion Sickness | Ear and labyrinth disorders | Tolvaptan (From Other: Tolvaptan) | 0 | 6 | 0 |
| other | Motion Sickness | Ear and labyrinth disorders | Tolvaptan (From Other: Placebo) | 1 | 3 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02251275/events